Maintaining consistent quality and clinical performance of biopharmaceuticals

ABSTRACT Introduction: Biopharmaceuticals are large protein based drugs which are heterogeneous by nature due to post translational modifications resulting from cellular production, processing and storage. Changes in the abundance of different variants over time are inherent to biopharmaceuticals due to their sensitivity to subtle process differences and the necessity for regular manufacturing changes. Product variability must thus be carefully controlled to ensure that it does not result in changes in safety or efficacy. Areas covered: The focus of this manuscript is to provide improved understanding of the science and strategies used to maintain the quality and clinical performance of biopharmaceuticals, including biosimilars, throughout their lifecycle. This review summarizes rare historical instances where clinically relevant changes have occurred, defined here as clinical drift, and discusses modern tools used to prevent such changes, including improved analytics, quality systems and regulatory frameworks. Expert opinion: Despite their size complexity and heterogeneity, modern analytics, manufacturing quality systems and comparability requirements for the evaluation of manufacturing changes cumulatively help to ensure the consistent quality and clinical performance of biopharmaceuticals throughout their product lifecycle. Physicians and patients can expect the same safety and efficacy from biopharmaceuticals and their respective biosimilars irrespective of batch or production history.

[1]  Heyi Li,et al.  Development and application of a robust N-glycan profiling method for heightened characterization of monoclonal antibodies and related glycoproteins. , 2014, Journal of pharmaceutical sciences.

[2]  Jinsu Song,et al.  Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar , 2017, mAbs.

[3]  Zsombor Zrubka,et al.  Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents , 2016, Current medical research and opinion.

[4]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[5]  Martin Schiestl,et al.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.

[6]  Albert J R Heck,et al.  Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry , 2017, Analytical chemistry.

[7]  Johann Holzmann,et al.  Top-down MS for rapid methionine oxidation site assignment in filgrastim , 2013, Analytical and Bioanalytical Chemistry.

[8]  Antonio Santoro,et al.  Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS) , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Allen R Nissenson,et al.  Epoetin‐associated pure red cell aplasia: past, present, and future considerations , 2008, Transfusion.

[10]  Siddharthan Chandran,et al.  Thrombotic microangiopathy associated with interferon beta. , 2014, The New England journal of medicine.

[11]  Yaning Wang,et al.  Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. , 2011, Analytical chemistry.

[12]  Alain Van Dorsselaer,et al.  Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. , 2012, Analytical chemistry.

[13]  Paolo Gallo,et al.  Immunogenicity of interferon beta: differences among products , 2004, Journal of Neurology.

[14]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[15]  Kai-Uwe Eckardt,et al.  Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Michael Leiss,et al.  Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry , 2015, mAbs.

[17]  Ali-Frédéric Ben-Amor,et al.  Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a , 2015, Advances in Therapy.

[18]  Wolfgang Lindner,et al.  HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals , 2010, Analytical and bioanalytical chemistry.

[19]  Johann Holzmann,et al.  Identification of Low-Level Product-Related Variants in Filgrastim Products Presently Available in Highly Regulated Markets , 2016, BioDrugs.

[20]  Richard M. Johnson.  Guideline on similar biological medicinal products , 2010 .

[21]  Alain Balland,et al.  Characterization of nonenzymatic glycation on a monoclonal antibody. , 2007, Analytical chemistry.

[22]  Christopher J Webster,et al.  A ‘Global Reference’ Comparator for Biosimilar Development , 2017, BioDrugs.

[23]  C. Schneider,et al.  Biosimilars in rheumatology: the wind of change , 2013, Annals of the rheumatic diseases.

[24]  Anthony Mire-Sluis,et al.  Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.

[25]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[26]  Johann Holzmann,et al.  The structure-function relationship of disulfide bonds in etanercept , 2017, Scientific Reports.

[27]  Richard S Rogers,et al.  Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics , 2015, mAbs.

[28]  Allen R Nissenson,et al.  Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.

[29]  Alain Van Dorsselaer,et al.  Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. , 2015, Journal of mass spectrometry : JMS.

[30]  Guideline on process validation for finished products - information and data to be provided in regulatory submissions , 2014 .

[31]  B Stubinski,et al.  Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results , 2009, Multiple sclerosis.

[32]  N. Bihoreau,et al.  Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: Case study after a long-term storage at +5°C. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  English Only,et al.  GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) , 2009 .

[34]  J. Venema,et al.  Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab) , 2015, mAbs.

[35]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[36]  Eric Chen,et al.  Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen , 2016, BMC Cancer.

[37]  Richard Pazdur,et al.  FDA's Approach to Regulating Biosimilars , 2016, Clinical Cancer Research.

[38]  Govert W Somsen,et al.  Detailed Characterization of Monoclonal Antibody Receptor Interaction Using Affinity Liquid Chromatography Hyphenated to Native Mass Spectrometry. , 2017, Analytical chemistry.

[39]  Safaraz K. Niazi.  Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[40]  Alain Balland,et al.  An optimized approach to the rapid assessment and detection of sequence variants in recombinant protein products , 2015, Analytical and Bioanalytical Chemistry.

[41]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[42]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[43]  Richard Pazdur,et al.  Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. , 2013, The oncologist.

[44]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .

[45]  Leon van Aerts,et al.  Interchangeability of Biosimilars: A European Perspective , 2017, BioDrugs.

[46]  Ying Qing Yu,et al.  N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. , 2014, Analytical chemistry.

[47]  N. Casadevall,et al.  The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. , 2005, Kidney international.

[48]  Y. Zhang,et al.  Domain-specific free thiol variant characterization of an IgG1 by reversed-phase high-performance liquid chromatography mass spectrometry. , 2017, Analytical biochemistry.

[49]  Johann Holzmann,et al.  Site-specific characterization and absolute quantification of pegfilgrastim oxidation by top-down high-performance liquid chromatography-mass spectrometry. , 2015, Analytical chemistry.

[50]  Jon Brumbaugh,et al.  DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION , 2000 .

[51]  John R. Engen,et al.  Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars , 2012, Nature Reviews Drug Discovery.

[52]  Donald E Walker,et al.  A modular and adaptive mass spectrometry-based platform for support of bioprocess development toward optimal host cell protein clearance , 2017, mAbs.

[53]  Yi Wang,et al.  Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion , 2016, mAbs.

[54]  Tilman Schlothauer,et al.  Functional assessment of antibody oxidation by native mass spectrometry , 2015, mAbs.

[55]  V. Reisinger,et al.  A mass spectrometry-based approach to host cell protein identification and its application in a comparability exercise. , 2014, Analytical biochemistry.

[56]  B. Kieseier.  The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis , 2011, CNS drugs.

[57]  Gustavo Grampp,et al.  Drift, Evolution, and Divergence in Biologics and Biosimilars Manufacturing , 2014, BioDrugs.

[58]  Luigi Murri,et al.  Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis , 2008, Neuropsychiatric disease and treatment.

[59]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[60]  Johann Holzmann,et al.  A direct-infusion- and HPLC-ESI-Orbitrap-MS approach for the characterization of intact PEGylated proteins. , 2014, Analytical chemistry.